MONTREAL, CANADA--(Marketwire - Feb 21, 2013) - Paladin Labs Inc. (PLB.TO), a leading Canadian specialty pharmaceutical company, will release its 2012 financial results on Thursday, February 28, 2013 prior to market opening. Following the release, Paladin will hold a conference call at 10:00 a.m. (EST) hosted by Mark Beaudet, interim President and CEO of Paladin Labs. Paladin cordially invites all interested parties to participate in this call.
CONFERENCE CALL DETAILS:
|DATE:||Thursday, February 28, 2013|
|TIME:||10:00 a.m. EST|
|DIAL IN NUMBER:||1-800-736-4594 OR 416-981-9000|
|TAPED REPLAY:||1- 800-558-5253 OR 416-626-4100
Available from Thursday, February 28, 2013 at 12:00 p.m. until Saturday, March 30, 2013 at midnight.
The call will also be audio-cast live and archived for 30 days at www.paladinlabs.com.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada''s leading specialty pharmaceutical companies. Paladin''s shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company''s web site at www.paladinlabs.com.
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company''s Annual Information Form for the year ended December 31, 2011. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company''s ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.
- Investment & Company Information
- pharmaceutical company